Monteloeder has developed a natural branded ingredient called Metabolaid; a plant-based product comprised of lemon verbena and hibiscus extracts. Monteloeder's clinical studies have shown that Metabolaid helps its users to lose weight by decreasing appetite and 'burning' abdominal fat, as well as improving obesity-related complications such as high blood pressure, high cholesterol levels and lower heart rate.
Obesity is currently one of the fastest-growing pandemics in the world, the prevalence of which has doubled since 1980. About a third of the world's population is overweight and the disease accounts for four million deaths a year. At this rate, it is estimated that in certain countries - such as the UK and US - about half of all adults will be categorised as obese by 2030.
With the help of the EU Horizon 2020 programme, Monteloeder will be able to further enhance the development and commercialisation of Metabolaid in an SME phase II project called Innoprefat. A unique and ambitious product, Innoprefat combines the use of a nutritional supplement for weight loss with the management of healthy habits. In this manner, Monteloeder has developed a mobile application that, combined with Metabolaid, helps consumers reach their goal weight.
The combination of digitisation and supplementation is the objective of a growing number of large companies in the health and digital sectors. In this aspect, Monteloeder is ahead of the game, as it already includes in its portfolio several products that combine supplementation with digital management, including Nutroxsun, an oral skincare product supported by a mobile app that manages your level of sun exposure.
Thanks to digitisation, personalised nutrition is possible as it allows you to measure a customer's habits, activity and consumption, and, in return, give them information on how to reach their goals. This is not possible with the nutraceutical alone as there would be no interaction between the company and the consumer, and a generic app does not give any information regarding a specific product. Therefore, it is necessary to combine the two apparently differing worlds of tech and supplementation in order to have a more complete health solution - one that can be measured, modified and customised. This is the true value of digitisation.
In fact, Monteloeder does not consider this approach as the development of a new product or service, but rather a global health solution. In this solution, it includes a branded ingredient formulated by the company and proven in the clinic to be highly efficient in improving a consumer's health in numerous areas including weight management, cardiovascular health and skincare. This is combined with a mobile application that allows customers to measure the effectiveness of the product and provides them with guidelines towards a healthy lifestyle.
Furthermore, unlike the classic approach to product development, the combination of a branded ingredient with an app results in a new concept of a 'living' product. In this sense, as technology advances and new results are observed with the branded ingredient, Monteloeder can rapidly modify the digital application with updates, continually improving its solution.
Besides branded ingredients such as Metabolaid and Nutroxsun, Monteloeder offers its digitisation services to other companies that wish to be part of the health 3.0 revolution, but do not have the tools or expertise. In this sense, there are three different scenarios in which the company can collaborate: creating a new digitised health ingredient from scratch, including participating in its design, development and clinical studies; digitising an already commercialised health ingredient, using the ingredient's current studies; and incorporating its expertise into a digitised health ingredient for further optimisation and efficiency.
Therefore, Monteloeder offers complete health solutions for any functional target, from weight management to sports performance.
The project has received funding from the EU Horizon 2020 research and innovation programme under grant agreement number 783838.